Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 176 for your search:
Cancer Type/Condition:
Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:
stage III chronic lymphocytic leukemia
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
POI-02818
, NIP-02-005, NCT00131313
2.
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
19 to 70
Sponsor:
Other
Protocol IDs:
F080429003
, UAB-0775, NCT00714259
3.
Stem Cell Transplant for Hematological Malignancy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
54 and under
Sponsor:
Other
Protocol IDs:
0107M05202
, MT2001-02, NCT00176930
4.
Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
NCI
Protocol IDs:
CBMTG-0601
, NCT00438958
5.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
6.
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
OMB110911
, EudraCT 2008-004932-19, NCT00748189
7.
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CC-5013-CLL-002
, NCT00774345
8.
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
110913
, NCT00824265
9.
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and ovr
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CC-5013-CLL-008
, Eudract #: 2008-003079-32, NCT00910910
10.
Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
NCI, Other
Protocol IDs:
09-073
, NCT00928018
11.
Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
12.
Phase I/II Study of Fludarabine and Thalidomide as Front-Line Therapy in Patients With Newly Diagnosed B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
RPCI-RPC-0112
, CELGENE-RPCI-RPC-0112, NCT00096018
13.
Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-05011-L
, OHSU-210, NCT00245037
14.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
15.
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
2006-0803
, NCT00410982
16.
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04U.115
, NCT00429416
17.
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-1026
, NCT00472849
18.
Phase I/II Randomized Pilot Study of Targeted Immune-Depleting Chemotherapy, Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation from an HLA-Matched Unrelated Donor, and Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus, Methotrexate, and Sirolimus Versus Alemtuzumab and Cyclosporine in Patients With High-Risk Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
19.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
20.
Phase I/II Study of CD40-Ligand Expressing and Interleukin-2 Gene Modified Autologous Tumor Cells in Patients With B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
BCM-H-19747
, H 19747, BCM-PRIMAL, NCT00602121
21.
Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
22.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
23.
Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MOZ00207
, NCT00694590
24.
Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
OHSU-4180
, 4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517
25.
Phase I/II Prospective Study of Nonmyeloablative Related Allogeneic HLA-Haploidentical Bone Marrow Transplantation Followed By Single Prophylactic Donor Lymphocyte Infusion of NK Cells in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2230.00
, 2230.00, IR-6771, NCT00789776
Select All on Page
1
Help with Results
